JP2018123122A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018123122A5 JP2018123122A5 JP2018008065A JP2018008065A JP2018123122A5 JP 2018123122 A5 JP2018123122 A5 JP 2018123122A5 JP 2018008065 A JP2018008065 A JP 2018008065A JP 2018008065 A JP2018008065 A JP 2018008065A JP 2018123122 A5 JP2018123122 A5 JP 2018123122A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- substituted
- independently
- replaced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 62
- 150000003839 salts Chemical class 0.000 claims 61
- 125000001072 heteroaryl group Chemical group 0.000 claims 30
- 229910052760 oxygen Inorganic materials 0.000 claims 30
- 229910052717 sulfur Inorganic materials 0.000 claims 28
- 125000005842 heteroatom Chemical group 0.000 claims 26
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 229910052757 nitrogen Inorganic materials 0.000 claims 20
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 18
- 125000004452 carbocyclyl group Chemical group 0.000 claims 18
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 17
- 150000001413 amino acids Chemical class 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 13
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- -1 4-{[(2S, 3R, 4R, 5S, 6S)- 3,5-Dihydroxy-4-methoxy-6-methyltetrahydro-2H-pyran-2-yl] oxy} -3-iodo-5,6-dimethoxy-2-methylbenzoyl Chemical group 0.000 claims 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000000107 disulfanyl group Chemical group [*]SS[H] 0.000 claims 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- 102000004641 Fetal Proteins Human genes 0.000 claims 1
- 108010003471 Fetal Proteins Proteins 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 1
- 229940126592 Ibritsumomab Drugs 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102100022338 Integrin alpha-M Human genes 0.000 claims 1
- 102100022337 Integrin alpha-V Human genes 0.000 claims 1
- 108060008539 Transglutaminase Proteins 0.000 claims 1
- 108010048673 Vitronectin Receptors Proteins 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 229960000548 alemtuzumab Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229960001776 edrecolomab Drugs 0.000 claims 1
- 229960000578 gemtuzumab Drugs 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 229960002450 ofatumumab Drugs 0.000 claims 1
- 229950007283 oregovomab Drugs 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 102000003601 transglutaminase Human genes 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 0 CCC(C(CC[C@@](C(C)OC(C1)O)C1C=N)C(C)C(C1O[C@@](C(*)C2C)OC(C)C2N=O)I)C1C(C)=C Chemical compound CCC(C(CC[C@@](C(C)OC(C1)O)C1C=N)C(C)C(C1O[C@@](C(*)C2C)OC(C)C2N=O)I)C1C(C)=C 0.000 description 3
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762449839P | 2017-01-24 | 2017-01-24 | |
| US62/449839 | 2017-01-24 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018123122A JP2018123122A (ja) | 2018-08-09 |
| JP2018123122A5 true JP2018123122A5 (cg-RX-API-DMAC10.html) | 2021-02-18 |
| JP7078405B2 JP7078405B2 (ja) | 2022-05-31 |
Family
ID=61168135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018008065A Active JP7078405B2 (ja) | 2017-01-24 | 2018-01-22 | カリケアマイシン誘導体およびその抗体薬物コンジュゲート |
Country Status (14)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| EP3573995A1 (en) * | 2017-01-24 | 2019-12-04 | Pfizer Inc. | Calicheamicin derivatives and antibody drug conjugates thereof |
| EP3720504A1 (en) * | 2017-12-06 | 2020-10-14 | Synaffix B.V. | Enediyne conjugates |
| EP3976112A1 (en) * | 2019-06-03 | 2022-04-06 | Synaffix B.V. | Acetal-based cleavable linkers |
| GB2585102B (en) | 2019-10-09 | 2021-06-30 | Audio Inventions Ltd | System for identification of a note played by a musical instrument |
| WO2025151608A1 (en) * | 2024-01-10 | 2025-07-17 | Systimmune, Inc. | Connecting units for ligand-drug conjugates and methods of making and using thereof |
| WO2026050757A2 (en) * | 2024-08-30 | 2026-03-05 | ALX Oncology Inc. | Calicheamicin derivatives and antibody-drug conjugates thereof |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2036891B (en) | 1978-12-05 | 1983-05-05 | Windsor Smith C | Change speed gear |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5606040A (en) * | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| EP0313874B1 (en) * | 1987-10-30 | 1994-04-13 | American Cyanamid Company | Disulfur analogs of LL-E33288 antitumor agents |
| US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| WO2005009882A1 (en) * | 2003-06-27 | 2005-02-03 | Otis Elevator Company | Absolute positioning system for elevators using dual encoders |
| HUE035853T2 (en) | 2005-07-18 | 2018-05-28 | Seattle Genetics Inc | Beta-glucuronide-linker-drug conjugates |
| EP1886696A1 (en) * | 2006-08-03 | 2008-02-13 | Endotis Pharma | Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| JP6055404B2 (ja) * | 2010-06-15 | 2016-12-27 | ゲンマブ エー／エス | 組織因子に対するヒト抗体薬物結合体 |
| SG186451A1 (en) | 2010-07-12 | 2013-01-30 | Covx Technologies Ireland Ltd | Multifunctional antibody conjugates |
| CA2813411C (en) | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| SG11201401699WA (en) | 2011-11-11 | 2014-09-26 | Rinat Neuroscience Corp | Antibodies specific for trop-2 and their uses |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| EP3539982B1 (en) | 2011-12-23 | 2025-02-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| MX340090B (es) | 2012-11-05 | 2016-06-23 | Pfizer | Analogos de spliceostatina. |
| US9453508B2 (en) | 2013-02-25 | 2016-09-27 | Asmo Co., Ltd. | Electric oil pump and hydraulic pressure supply device |
| KR101614151B1 (ko) | 2014-07-01 | 2016-04-22 | 한국화학연구원 | 흡입 독성 시험용 폐 모델 장치 |
| HUE049325T2 (hu) | 2014-08-28 | 2020-09-28 | Pfizer | Stabilitás modulátor linker antitest-hatóanyag konjugátumokhoz történõ alkalmazásra |
| JP6852065B2 (ja) | 2015-10-20 | 2021-03-31 | ジェネンテック， インコーポレイテッド | カリケアマイシン−抗体−薬物コンジュゲート及び使用方法 |
| WO2017172907A1 (en) | 2016-03-29 | 2017-10-05 | Sorrento Therapeutics, Inc. | Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin |
| WO2018069851A2 (en) | 2016-10-11 | 2018-04-19 | Sorrento Therapeutics, Inc. | C-met antibody drug conjugate |
| EP3573995A1 (en) * | 2017-01-24 | 2019-12-04 | Pfizer Inc. | Calicheamicin derivatives and antibody drug conjugates thereof |
-
2018
- 2018-01-10 EP EP18703623.1A patent/EP3573995A1/en not_active Withdrawn
- 2018-01-10 US US16/477,290 patent/US11993625B2/en active Active
- 2018-01-10 CN CN201880020707.5A patent/CN110461860A/zh active Pending
- 2018-01-10 AU AU2018211561A patent/AU2018211561B2/en not_active Ceased
- 2018-01-10 WO PCT/IB2018/050153 patent/WO2018138591A1/en not_active Ceased
- 2018-01-10 MX MX2019008773A patent/MX2019008773A/es unknown
- 2018-01-10 BR BR112019015069-2A patent/BR112019015069A2/pt not_active Application Discontinuation
- 2018-01-10 CA CA3051038A patent/CA3051038C/en active Active
- 2018-01-10 RU RU2019123161A patent/RU2732568C1/ru active
- 2018-01-10 SG SG11201906414VA patent/SG11201906414VA/en unknown
- 2018-01-10 KR KR1020197024719A patent/KR20190111086A/ko not_active Withdrawn
- 2018-01-22 JP JP2018008065A patent/JP7078405B2/ja active Active
- 2018-01-23 TW TW107102314A patent/TWI687221B/zh not_active IP Right Cessation
-
2019
- 2019-07-24 IL IL268245A patent/IL268245A/en unknown
-
2024
- 2024-04-05 US US18/627,949 patent/US20240409573A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7190549B2 (ja) | Ｈｄａｃ阻害剤とｐｄ－１阻害剤との組み合わせ療法 | |
| US10933071B2 (en) | Polyethylene glycol-conjugated glucocorticoid prodrugs and compositions and methods thereof | |
| US12533411B2 (en) | Compositions comprising anti-CD38 antibodies and carfilzomib | |
| CA2991975C (en) | Novel linkers and their uses in specific conjugation of drugs to a biological molecule | |
| ES2477765T3 (es) | Agentes de unión al anti-cd70 humanizado y usos de los mismos | |
| RU2015156499A (ru) | Конъюгаты антитела с лекарственным средством | |
| US20240366756A1 (en) | Combinations and uses thereof | |
| AU2015243379B2 (en) | Tubulysin derivatives | |
| KR20210008008A (ko) | 항-msr1 항체 및 이의 사용 방법 | |
| JP2012522513A5 (cg-RX-API-DMAC10.html) | ||
| JP2025510606A5 (cg-RX-API-DMAC10.html) | ||
| RU2015115954A (ru) | Аналоги сплицеостатина | |
| JP2022185004A5 (cg-RX-API-DMAC10.html) | ||
| RU2014124984A (ru) | Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы | |
| EP4319739A2 (en) | Combination therapies with cbl-b inhibitor compounds | |
| AU2012296907A1 (en) | Combination therapy with an anti - CD19 antibody and a nitrogen mustard | |
| TW202229344A (zh) | 抗-cd40抗體用於治療發炎病況之用途 | |
| JP2019507126A5 (cg-RX-API-DMAC10.html) | ||
| EP2766045B1 (en) | Treatment of breast cancer with companion diagnostic | |
| JP2024533426A5 (cg-RX-API-DMAC10.html) | ||
| JP2024507986A5 (cg-RX-API-DMAC10.html) | ||
| RU2025131232A (ru) | Конъюгат антитело анти-cdh6-лекарственное средство и его применение | |
| EA047718B1 (ru) | Способ модуляции сигнальных путей tigit и pd-1 с применением 1,2,4-оксадиазольных соединений |